Industry news
-
Semaglutide is not just for weight loss
Semaglutide is a glucose-lowering drug developed by Novo Nordisk for the treatment of type 2 diabetes. In June 2021, the FDA approved Semaglutide for marketing as a weight loss drug (trade name Wegovy). The drug is a glucagon-like peptide 1 (GLP-1) receptor agonist that can mimic its effects, red...Read more -
What is Mounjaro(Tirzepatide)?
Mounjaro(Tirzepatide) is a drug for weight loss and maintenance that contains the active substance tirzepatide. Tirzepatide is a long-acting dual GIP and GLP-1 receptor agonist. Both receptors are found in pancreatic alpha and beta endocrine cells, heart, blood vessels, ...Read more -
Tadalafil Application
Tadalafil is a medication used to treat erectile dysfunction and certain symptoms of an enlarged prostate. It works by improving blood flow to the penis, enabling a man to achieve and maintain an erection. Tadalafil belongs to a class of drugs known as phosphodiesterase type 5 (PDE5) inhibitors, ...Read more -
New Products Alert
In order to provide more options to the clients in Cosmetic peptides industry, Gentolex will constantly add new products to the list. High quality with varieties categories, there are totally four different series defined by functions in protecting skins, including Anti-aging & anti-wrinkle, ...Read more -
The research progress of opioid peptides from the approval of Difelikefalin
As early as 2021-08-24, Cara Therapeutics and its business partner Vifor Pharma announced that its first-in-class kappa opioid receptor agonist difelikefalin (KORSUVA™) was approved by the FDA for the treatment of chronic kidney disease (CKD) patients (positive Moderate/severe pruritus with hemod...Read more